Phesgo-600mg/600mg. (Pertuzumab - Trastuzumab Vials) 600mg/600mg

Phesgo-600mg/600mg is a combination therapy in vial form, combining pertuzumab and trastuzumab for targeted cancer treatment. This fixed-dose regimen supports HER2-positive breast cancer management. Store between 2-8°C to maintain potency. Suitable for adult oncology protocols.

Strength

600mg/600mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

ROCHE PHARMA AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Phesgo-600mg/600mg is used in combination with chemotherapy to treat HER2-positive breast cancer in adults. It targets specific proteins to slow or stop cancer cell growth. This therapy is often prescribed after surgery or for metastatic cases. Patients may ask, 'what is Phesgo used for' when exploring treatment options.

Side Effects

Phesgo-600mg/600mg may cause fatigue, nausea, or diarrhea as common effects. Some users report headaches or infusion-related reactions like chills or fever. These effects vary by individual and are typically monitored during therapy. Regular check-ups help manage any discomfort.

Precautions & Warnings

Keep Phesgo-600mg/600mg refrigerated between 2-8°C and protect from light. Avoid freezing or shaking the vials. Handle with care to prevent contamination, and dispose of used materials properly. Always follow healthcare provider instructions for safe storage and administration.

Avoid Interactions

Phesgo-600mg/600mg may interact with other medications, including certain chemotherapy drugs or immune suppressants. Avoid live vaccines during treatment due to potential reduced effectiveness. Discuss all current medications with your healthcare provider to minimize risks.

Frequently Asked Questions

Phesgo is used to treat HER2-positive breast cancer in adults, often in combination with chemotherapy.

Phesgo is given as an intravenous infusion by a healthcare professional in a clinical setting.

No, Phesgo must be refrigerated between 2-8°C to maintain its effectiveness.

Common side effects include fatigue, nausea, diarrhea, headaches, and infusion-related reactions like chills.

Yes, it may interact with certain drugs, including chemotherapy and live vaccines; consult your doctor.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.